Preservation with 8-bromo-cyclic GMP improves pulmonary function after prolonged ischemia.
BACKGROUND
Cyclic guanosine monophosphate (cGMP) is a potent second messenger for the nitric oxide pathway in the pulmonary vasculature. Increased cytosolic cGMP levels elicit pulmonary vasodilatation resulting in decreased pulmonary vascular resistance and maximized pulmonary function after ischemia-reperfusion injury. We hypothesized that the addition of a membrane-permeable cGMP analogue (8-bromo-cGMP) to a Euro-Collins (EC) preservation solution would ameliorate pulmonary reperfusion injury better than prostaglandin E1 injection alone after prolonged hypothermic ischemia.


METHODS
All lungs from New Zealand White rabbits (weight, 3 to 3.5 kg) were harvested en bloc, flushed with EC solution, and reperfused with whole blood for 30 minutes. Group 1 lungs (immediate control) were immediately reperfused. Group 2 lungs (control) were stored inflated at 4 degrees C for 18 hours before reperfusion. Groups 3 and 4 lungs were flushed with EC solution containing 200 micromol/L 8-bromo-cGMP and stored at 4 degrees C for 18 and 30 hours, respectively. Fresh, nonrecirculated venous blood was used to determine single-pass pulmonary venous-arterial oxygen gradients at 10-minute intervals. Assays for cGMP, cyclic adenosine monophosphate, nitric oxide synthase activity, and myeloperoxidase were performed on all lung tissue samples. Wet to dry weight ratios were determined after 2 weeks of passive desiccation.


RESULTS
Oxygenation (venous-arterial oxygen gradient), pulmonary artery pressure, pulmonary vascular resistance, and edema formation were significantly improved in groups 3 and 4 (addition of 8-bromo-cGMP to EC plus 18 or 30 hours of hypothermic ischemia). Hypothermic storage (groups 2, 3, and 4) decreased both nitric oxide synthase activity and myeloperoxidase levels compared with immediate reperfusion (group 1).


CONCLUSIONS
These results suggest that the addition of a membrane-permeable cGMP analogue to an EC pulmonary flush solution improves pulmonary function after prolonged storage compared with EC and prostaglandin (E1) preservation alone. The finding of myeloperoxidase reduced levels after hypothermic storage and subsequent reperfusion may suggest a more important role for pulmonary hemodynamic control in mitigating pulmonary reperfusion injury.
King
R C
RC
Department of Surgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
Laubach
V E
VE
Kanithanon
R C
RC
Kron
A M
AM
Parrino
P E
PE
Shockey
K S
KS
Tribble
C G
CG
Kron
I L
IL
D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure; D000242:Cyclic AMP / Q000032:analysis; D006152:Cyclic GMP / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000032:analysis / Q000494:pharmacology; D006982:Hypertonic Solutions; D008168:Lung / Q000187:drug effects*; D019001:Nitric Oxide Synthase / Q000032:analysis; D009926:Organ Preservation / Q000379:methods; D019188:Organ Preservation Solutions; D010100:Oxygen / Q000097:blood; D009195:Peroxidase / Q000032:analysis; D011651:Pulmonary Artery / Q000502:physiology; D011652:Pulmonary Circulation; D011817:Rabbits; D015427:Reperfusion Injury / Q000517:prevention & control*; D014655:Vascular Resistance
C037096:Euro-Collins' solution; D006982:Hypertonic Solutions; D019188:Organ Preservation Solutions; C016276:8-bromocyclic GMP; D000242:Cyclic AMP; D009195:Peroxidase; D019001:Nitric Oxide Synthase; D000527:Alprostadil; D006152:Cyclic GMP; D010100:Oxygen